Investing19d
Aandelen OS Therapies schieten omhoog na succes fase 2b-studie
Investing.com -- De aandelen van OS Therapies, Inc. (NYSE-A: OSTX) stegen met 58% na de bekendmaking van positieve resultaten uit hun fase 2b klinische studie voor OST-HER2, een ...
American Association of Individual Investors5d
Why OS Therapies Incorporated’s (OSTX) Stock Is Down 25.00%
Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate OS Therapies Incorporated before investing. In this article, we go over a few key ...
Investing17d
OS Therapies ziet aandelenverkoop van €112.609 door Einodmil LLC
ROCKVILLE, Md.—OS Therapies Inc. (NASDAQ:OSTX), een farmaceutisch bedrijf met een marktkapitalisatie van €87,5 miljoen, zag onlangs een significante transactie waarbij Einodmil LLC, een 10% eigenaar ...
ETF Daily News4d
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals: MarketBeat News
As per the terms of the agreement, OS Therapies will pay an aggregate purchase price of $8 million. This will include $0.5 million in cash and $7.5 million worth of OS Therapies’ common shares.
Yahoo Finance3d
OS Therapies Incorporated (OSTX)
OS Therapies (OSTX) announced it has entered into an asset purchase agreement to acquire the listeria monocytogenes-based immuno-oncology programs and related intellectual property assets from ...
Business Wire5d
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate ...
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it ...
Yahoo Finance4d
OS Therapies to acquire listeria programs from Ayala Pharmaceuticals
OS Therapies (OSTX) announced it has entered into an asset purchase agreement to acquire the listeria monocytogenes-based immuno-oncology programs and related intellectual property assets from ...
Business Insider3d
OS Therapies files to sell 10.83M shares of common stock for holders
16:24 EST OS Therapies (OSTX) files to sell 10.83M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.
FierceBiotech19d
OS Therapies' HER2 drug prevented lung cancer from returning in a 3rd of patients
OS Therapies’ HER2-focused immunotherapy prevented patients’ lung cancer from returning in 33% of cases, hitting the primary goal of a phase 2 trial. The therapy, dubbed OST-HER2, uses a HER2 ...
Investing20d
OS Therapies concludes $7.1M private placement
OS Therapies Inc (NYSE American:OSTX), a biopharmaceutical company specializing in antibody-drug conjugates (ADC) and immunotherapy, announced the completion of its private placement, raising ...
Investing20d
OS Therapies closes additional private placement round
OS Therapies Inc (NYSE American:OSTX), a biopharmaceutical company specializing in ADC and immunotherapy with a current market capitalization of $98.76 million, has completed a second private ...